IntelliAM aiming for significant growth with £5 million Aquis IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksETX.L Regulatory News (ETX)

  • There is currently no data for ETX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Issue of Equity

29 Apr 2010 09:02

RNS Number : 0230L
e-Therapeutics plc
29 April 2010
 



e-Therapeutics plc

('e-Therapeutics' or 'the Company')

 

Issue of Equity and Director's award of Options

 

e-Therapeutics plc (AIM: ETX), the systems biology drug discovery company, announces that on 28 April 2010 , the Company issued and allotted 466,460 ordinary shares of 0.1p each in the Company (' Ordinary Shares') in order to satisfy the exercise of certain options.

 

Application has been made to admit the new Ordinary Shares to trading on AIM and dealings in the new Ordinary Shares are expected to commence on 5 May 2010. Following admission the number of Ordinary Shares in issue in the Company will be 65,886,752.

 

The above figure (65,886,752 Ordinary Shares) may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, e-Therapeutics plc under the FSA's Disclosure and Transparency Rules.

 

In addition to the above, two directors of the Company being Mr Oliver James and Mr Brad Hoy were both granted option over 25,000 ordinary shares in the Company at an exercise price of £0.385 and which have a vesting period of 3 years. Following this grant Mr James and Mr Hoy have the following interests in ordinary shares of the Company:

 

Name

Ordinary Shares owned

Options over Ordinary Shares

Number

Number

Exercise Price

Date at which exercisable

Oliver James

38,500

118,020

£0.67

Vested

25,000

£0.385

28 April 2013

Brad Hoy

80,000

£0.375

Vested

25,000

£0.385

28 April 2013

 

 

 

- Ends -

 

 

For more information:

e-Therapeutics plc

www.etherapeutics.co.uk

Malcolm Young

malcolm@etherapeutics.co.uk

+44 (0) 191 233 1317

Nominated Advisor & Broker:

Canaccord Adams Ltd

www.canaccordadams.com

Robert Finlay / Henry Fitzgerald-O'Connor

henry.fitzgerald-o'connor@canaccordadams.com

+44 (0) 20 7050 6500

Media enquiries:

Abchurch Communications

www.abchurch-group.com

Heather Salmond / Simone Elviss / Hannah Sharman

simone.elviss@abchurch-group.com

+44 (0) 20 7398 7700

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IOESEFSAUFSSESL
Date   Source Headline
11th Feb 20207:00 amRNSBoard Changes and Placing
13th Jan 202012:58 pmRNSCorrection - Director/PDMR Shareholding
2nd Jan 20203:28 pmRNSDirector/PDMR Shareholding
8th Nov 201910:54 amRNSHolding(s) in Company
29th Oct 20194:10 pmRNSHolding(s) in Company
28th Oct 20192:36 pmRNSHolding(s) in Company
28th Oct 201912:05 pmRNSHolding(s) in Company
28th Oct 20198:00 amRNSHolding(s) in Company
7th Oct 20197:00 amRNSHalf-year Report
17th Sep 20194:41 pmRNSHolding(s) in Company
4th Sep 20192:05 pmRNSSecond Price Monitoring Extn
4th Sep 20192:00 pmRNSPrice Monitoring Extension
4th Sep 201911:05 amRNSSecond Price Monitoring Extn
4th Sep 201911:00 amRNSPrice Monitoring Extension
23rd Aug 201911:21 amRNSHolding(s) in Company
22nd Aug 201911:42 amRNSHolding(s) in Company
13th Aug 20197:00 amRNSe-therapeutics to work with top pharma company
1st Aug 20197:00 amRNSExtends Research Collaboration with Novo Nordisk
15th Jul 20192:06 pmRNSSecond Price Monitoring Extn
15th Jul 20192:00 pmRNSPrice Monitoring Extension
2nd Jul 20197:00 amRNSDirector/PDMR Shareholding
28th Jun 20192:06 pmRNSSecond Price Monitoring Extn
28th Jun 20192:00 pmRNSPrice Monitoring Extension
27th Jun 20193:17 pmRNSHolding(s) in Company
26th Jun 20194:41 pmRNSHolding(s) in Company
6th Jun 20193:58 pmRNSHolding(s) in Company
30th Apr 201911:21 amRNSResult of AGM
2nd Apr 20197:00 amRNSDirector/PDMR Shareholding
29th Mar 201910:00 amRNSDirector/PDMR Shareholding
20th Mar 201911:05 amRNSSecond Price Monitoring Extn
20th Mar 201911:00 amRNSPrice Monitoring Extension
14th Mar 201912:39 pmEQSEdison issues outlook on Jersey Electricity (JEL)
8th Mar 201910:30 amRNSNotice of Annual General Meeting and Annual Report
5th Mar 20193:51 pmEQSEdison issues update on e-Therapeutics (ETX)
5th Mar 20197:00 amRNSFull Year Results
20th Feb 20197:00 amRNSNotification of Full Year Results Date
3rd Jan 20199:00 amRNSDirector/PDMR Shareholding
12th Dec 20181:01 pmEQSEdison Investment Research Limited: Edison issues outlook on e-Therapeutics (ETX)
10th Dec 20187:00 amRNSResearch Collaboration Agreement with Novo Nordisk
6th Dec 201810:36 amEQSEdison Investment Research Limited: Edison issues update on e-Therapeutics (ETX)
6th Dec 20187:00 amRNSE-therapeutics and C4X Collaboration
29th Nov 20187:00 amRNSDrug Discovery Innovation Programme Presentation
12th Nov 201811:30 amRNSe-therapeutics to present at BioCentury Summit
5th Nov 20187:00 amRNSHolding(s) in Company
8th Oct 201810:42 amEQSEdison issues update on e-Therapeutics (ETX)
4th Oct 20187:00 amRNSInterim Results for six months ended 31 July 2018
17th Sep 201811:30 amRNSNotice of Interim Results
9th Aug 20187:00 amRNSDirector Shareholding
7th Aug 20187:00 amRNSDirector/PDMR Shareholding
3rd Jul 20182:08 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.